Title: Biodistribution, dosimetry and imaging of 225Ac-DOTA-anti-PD-L1-BC in a murine immunocompetent transgenic breast cancer model
Authors: JOSEFSSON ANDERSNEDROW JESSIEPARK SUNJUBAECK TOMHOBBS ROBERT F.BRAYTON CORYBRUCHERTSEIFER FRANKMORGENSTERN ALFREDSGOUROS G.
Publisher: European Commission - Joint Research Centre
Publication Year: 2017
JRC N°: JRC106150
URI: http://nucmed.w3.kanazawa-u.ac.jp/symposium/tat10/
http://publications.jrc.ec.europa.eu/repository/handle/JRC106150
Type: Articles in periodicals and books
Abstract: The recent development of immunomodulatory agents have brought immunotherapy up as a possible treatment against various types of cancers. This treatment approach is based on tumors avoiding immune system recognition by co-opting immune checkpoints intended to prevent autoimmunity. One of the immune checkpoint mediators is the Programmed Cell Death protein 1 (PD-1) receptor. PD-1 interacts with Programmed cell Death Ligand 1 (PD-L1). PD-L1 is expressed on a variety of tumor cells, tumor associated macrophages and other cells in the tumor microenvironment. Clinical trials of anti-PD-L1 antibodies have yielded promising results in patient populations, which have exhausted all other conventional therapeutic options. In addition a number of studies have shown the potential of combined immune checkpoint inhibition therapy and external beam radiotherapy. In this study we examine the feasibility of a 225Ac-labeled anti-PD-L1 antibody to deliver an alpha-particle emitting radionuclide in a murine immunocompetent transgenic breast cancer model.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.